VivoSeq
Infectious Disease

Helicobacter

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Helicobacter is an early-stage landscape with 0 programs across 1 company. The most active players are International Pharmaceutical Consultancy.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

International Pharmaceutical Consultancy

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Withdrawn1 · 25%

Clinical Trials

Trial Activity

Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
Completed·—·Phase 4·NCT06168084·688 enrolled
Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04678492·658 enrolled
Sensitivity and Specificity of the Modified Helicobacter Test INFAI
Withdrawn·IInternational Pharmaceutical Consultancy·N/A·NCT04294823
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT03609892·658 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)